Wegovy and Acetaminophen Interaction: What Patients Need to Know

How Semaglutide Affects Acetaminophen Absorption

Semaglutide, the active compound in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that slows gastric emptying as part of its mechanism of action. This delay affects how quickly co-administered oral medications reach the small intestine, where most absorption occurs. Acetaminophen is a well-established pharmacokinetic probe drug used specifically to measure gastric emptying rate in clinical studies [1].

When a patient takes acetaminophen while on steady-state semaglutide, the drug sits in the stomach longer before moving into the duodenum. The result is a lower peak plasma concentration (Cmax) and a later time to peak (Tmax). Total drug exposure, measured by area under the curve (AUC), stays within a clinically acceptable range [2]. This means acetaminophen still works. It just takes longer to kick in.

The Wegovy prescribing information confirms this effect directly. In a dedicated drug interaction study, 1,000 mg of acetaminophen was administered to subjects on semaglutide 1 mg (the subcutaneous dose used in the interaction trial). Acetaminophen Cmax decreased by approximately 23%, and Tmax was delayed by about 1 hour [3]. These findings are consistent across the GLP-1 receptor agonist class, as drugs like liraglutide and dulaglutide produce similar gastric emptying delays [4].

What the FDA Label States About This Interaction

The Wegovy prescribing information addresses concomitant oral medication use in Section 7 (Drug Interactions). The label notes that semaglutide "causes a delay of gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications" [3]. For acetaminophen specifically, the label cites pharmacokinetic data showing reduced Cmax and delayed Tmax without a meaningful change in AUC.

The FDA did not require a boxed warning, contraindication, or dose modification for this combination. The agency's position reflects the fact that total acetaminophen exposure is preserved. Dr. Jens Juul Holst, a pioneer in GLP-1 physiology at the University of Copenhagen, has noted: "The delay in gastric emptying caused by GLP-1 receptor agonists is most pronounced after the first few doses and tends to attenuate with continued treatment, which is why the absorption changes for co-administered drugs are generally modest" [5].

This attenuation effect is clinically relevant. Patients in the early weeks of Wegovy titration (0.25 mg to 0.5 mg) may experience more pronounced gastric slowing than those on the maintenance dose of 2.4 mg for several months. The interaction does not worsen over time [3].

Pharmacokinetic Data in Detail

The dedicated interaction study in the Wegovy label used a crossover design. Subjects received a single 1,000 mg dose of acetaminophen with and without steady-state semaglutide. Three key parameters were measured [3]:

Cmax (peak concentration): Acetaminophen Cmax fell by 23% (geometric mean ratio 0.77, 90% CI 0.61 to 0.97). This reduction means the highest blood level of acetaminophen is lower, which could translate to a slightly slower onset of pain relief.

Tmax (time to peak): Median Tmax shifted from 0.5 hours to approximately 1.5 hours. Pain relief that a patient might expect within 20 to 30 minutes could take closer to 45 to 60 minutes.

AUC (total exposure): The AUC ratio remained near 1.0, indicating that the total amount of acetaminophen absorbed over time was not clinically different. The drug gets in. It just arrives on a slower schedule.

These numbers are consistent with data from the oral semaglutide (Rybelsus) program. A pharmacokinetic sub-study published in Clinical Pharmacokinetics found that oral semaglutide 14 mg delayed acetaminophen Tmax by a median of 0.5 hours and reduced Cmax by 13 to 27%, again without AUC changes meeting the threshold for clinical concern [6]. The effect size is comparable across subcutaneous and oral formulations because both activate the same GLP-1 receptors in the gut and central nervous system that regulate gastric motility.

A separate gastric emptying study using the acetaminophen absorption test in 30 subjects receiving semaglutide 1 mg subcutaneously showed that postprandial gastric emptying was delayed during the first hour after a meal, with the AUC of acetaminophen in the first hour (AUC0-1h) reduced by 27% [7]. After 5 hours, cumulative absorption was equivalent between the semaglutide and placebo arms.

Hepatic Safety: Do These Drugs Overlap in Liver Risk?

Acetaminophen is metabolized primarily in the liver via glucuronidation (40 to 67% of the dose), sulfation (20 to 46%), and a smaller fraction through CYP2E1 to form the reactive metabolite NAPQI [8]. At therapeutic doses (up to 3,000 mg per day for adults, per current FDA guidance), glutathione stores neutralize NAPQI efficiently. Hepatotoxicity occurs when doses exceed 4,000 mg per day or when glutathione is depleted by fasting, alcohol use, or malnutrition [9].

Semaglutide has a different hepatic profile. It is not metabolized through cytochrome P450 enzymes. Instead, it undergoes proteolytic cleavage and beta-oxidation of the fatty acid side chain [3]. GLP-1 receptor agonists have shown hepatoprotective signals in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg reduced alanine aminotransferase (ALT) levels by a mean of 9.5% from baseline at 68 weeks, compared to 1.2% with placebo [10].

The 2023 American Association for the Study of Liver Diseases (AASLD) practice guidance on MASLD states: "GLP-1 receptor agonists may be considered for patients with MASLD and type 2 diabetes or obesity, given evidence of histologic improvement in steatohepatitis" [11]. There is no evidence that semaglutide potentiates acetaminophen hepatotoxicity at any dose level studied in clinical trials.

Patients should still observe the standard acetaminophen ceiling. For adults without liver disease, the FDA recommends no more than 3,000 mg per day from all sources (including combination products like cold medicines). For patients with pre-existing liver disease or heavy alcohol use, many hepatologists recommend a lower ceiling of 2,000 mg per day [9].

Practical Dosing Guidance for Patients

No dose adjustment is needed for acetaminophen when taking Wegovy. The clinical approach is straightforward.

For acute pain or fever, take acetaminophen at standard doses (500 to 1,000 mg every 4 to 6 hours, not exceeding 3,000 mg in 24 hours). Expect that pain relief may begin 15 to 30 minutes later than usual. If using acetaminophen for time-sensitive relief (such as pre-procedure dosing), consider taking it 30 minutes earlier than you normally would to account for the gastric emptying delay.

For chronic or scheduled dosing (such as osteoarthritis management), the delayed peak is largely irrelevant because steady-state acetaminophen levels are maintained by the regular dosing interval. The AUC is unchanged, so efficacy at steady state should be equivalent [3].

Keep a running count of all acetaminophen intake, including hidden sources. Over 600 prescription and over-the-counter products contain acetaminophen in the United States [12]. Common combination products include hydrocodone/acetaminophen (Vicodin), oxycodone/acetaminophen (Percocet), and numerous cold/flu formulations (NyQuil, DayQuil, Excedrin).

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity advises clinicians to "review all concomitant medications when initiating GLP-1 receptor agonist therapy, particularly oral drugs with narrow therapeutic indices or time-sensitive absorption requirements" [13]. Acetaminophen does not fall into the narrow therapeutic index category, which is why no dosing change is warranted.

When to Contact Your Prescriber

Most patients can take Wegovy and acetaminophen together without any issues. Contact your prescriber if you experience any of the following:

Persistent nausea or vomiting that prevents you from keeping oral medications down. Semaglutide-related nausea occurs in approximately 44% of patients during dose escalation in the STEP-1 trial [10], and severe nausea can impair absorption of any oral drug regardless of gastric emptying changes.

Signs of liver injury (yellowing of the skin or eyes, dark urine, severe right upper quadrant pain, unexplained fatigue). While the combination is not hepatotoxic at recommended doses, these symptoms warrant immediate evaluation to rule out unrelated causes.

Need for a medication with a narrow therapeutic index. Drugs like warfarin, phenytoin, or levothyroxine require tighter absorption control, and the gastric emptying delay from semaglutide may have more clinically meaningful effects on these agents [3]. If you take any of these drugs, your prescriber may want to check levels more frequently during Wegovy titration.

Acetaminophen doses exceeding 2,000 mg per day combined with any of the following: regular alcohol use (3 or more drinks per day), BMI <18.5, or known liver disease. These patients have reduced glutathione reserves and may be more susceptible to NAPQI-mediated injury [9].

Other Wegovy Drug Interactions Worth Knowing

The gastric emptying effect of semaglutide is not specific to acetaminophen. It applies to all oral medications to varying degrees. The FDA label highlights several co-administered drugs that were studied in dedicated interaction trials [3]:

Oral contraceptives (ethinyl estradiol/levonorgestrel): Cmax of ethinyl estradiol decreased by 12% and levonorgestrel Cmax decreased by 12%. AUC was unchanged for both. No dose adjustment or backup contraception is required [3].

Atorvastatin: Cmax decreased by 38% and AUC decreased by 5%. The statin remains effective because LDL reduction correlates with AUC rather than Cmax [14].

Digoxin: Cmax decreased by 22%, AUC decreased by 3%. Given digoxin's narrow therapeutic index, monitoring serum levels during semaglutide initiation is reasonable [3].

Warfarin: Semaglutide did not produce clinically relevant changes in warfarin exposure (R-warfarin or S-warfarin AUC and Cmax ratios were within the 80 to 125% bioequivalence window) [3]. The American College of Cardiology recommends checking INR more frequently during the first 4 to 8 weeks of GLP-1 RA therapy in warfarin-treated patients as a precaution [15].

Metformin: No clinically significant interaction. Metformin is absorbed in the small intestine, and its absorption profile was not meaningfully altered by semaglutide in pharmacokinetic studies [3].

For patients on multiple oral medications, the simplest strategy is to maintain consistent timing relative to meals and semaglutide injections. Semaglutide is dosed once weekly, and gastric emptying effects are present throughout the dosing interval, so separating oral medications from the injection day does not avoid the interaction [3].

The standard adult maximum for acetaminophen from all sources is 3,000 mg per day, and patients on Wegovy should track combination products that contain acetaminophen alongside their standalone doses [12].